Status: Recruiting
R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors
The goal of this study is determine the safety and tolerability of orally taken probiotic (R-5780) in patients currently on a PD-1 Pathway Checkpoint Inhibitor (checkpoint protein on immune cells called T cells) with Solid Tumors.
Participants needed: 33
Trial details
Phase: Phase 1Age: 18-80Biological sex: AllType: InterventionalSponsor: Rise Therapeutics LLCUpdated: Sep 4, 2025Locations: 1
Eligibility criteria
At least 18 years of age to 80 [+6]
Any serious medical condition or laboratory abnormality or psychiatric condition... [+13]